2022 Revenues ($USD) : $473,438,000
2022 R&D spend : $56,306,000
2022 Number of Employees : 1,400
Fiscal Year End : 12/31/2021
Company CEO : Thomas Sullivan, CEO

Founded in 1987, Natus Medical focuses on developing technologies to screen, diagnose and treat disorders involving the brain and nervous system. In July, the investment firm ArchiMed acquired Natus for $1.2 billion. Formerly publicly traded, Natus is now a privately-held $500 million portfolio company of ArchiMed. On its website, Natus Medical boasts that it provides a "complete portfolio of neurodiagnostic supplies." The company currently manufactures technologies for applications in electroencephalography, polysomnography, neurosurgery, neurocritical care and brain injury, among others. In late 2021, Natus named Thomas Sullivan its new president and CEO. –BB